🟢 GT Biopharma is trading 6% up in pre-market with no identified company-specific explanation

GT Biopharma is trading 5.64% higher at $6.56 in pre-market, with no company-specific announcement identified to explain the move. - A resale registration for up to 13,502,835 shares was reported October 14, but it concerns a prior filing and does not establish a cause for the gain. - Broader markets were under pressure after hotter-than-expected U.S. inflation; Reuters reported declines in Asian equities and technology shares, but that context does not explain the move higher.